A facility for magnetic resonance-guided radiation therapy.

Magnetic resonance (MR) imaging is routinely employed in the design of radiotherapy (RT) treatment plans for many disease sites. It is evident that tighter integration of MR imaging into the RT process would increase confidence in dose placement and facilitate the integration of new MR imaging information (including anatomical and functional imaging) into the therapy process. To this end, a dedicated MR-guided RT (MRgRT) facility has been created that integrates a state-of-the-art linear accelerator delivery system, high-dose rate brachytherapy afterloader, and superconducting MR scanner to allow MR-based online treatment guidance, adaptive replanning, and response monitoring while maintaining the clinical functionality of the existing delivery systems. This system is housed within a dedicated MRgRT suite and operates in a coordinated fashion to assure safe and efficient MRgRT treatments.

Transit dose contributions to intracavitary and interstitial PDR brachytherapy treatments.

The objective of this study was to determine the magnitude of transit dose contributions to the planned dose in common intracavitary and interstitial brachytherapy treatments delivered using a pulsed dose rate (PDR) remote afterloader. The total transit dose arises from the travel of the radiation source into (entry) and out of (exit) the applicator, and between the dwell positions (inter-dwell). In this paper, we used a well-type ionization chamber to measure the transit dose component for a PDR afterloader and compared the results against measurements for a high dose rate (HDR) afterloader. Our results show that for typical intracavitary and interstitial treatments, the major contribution to transit dose is from the entry+exit source travel, as the inter-dwell component is effectively compensated for (<0.5%) by the afterloader. The transit dose was generally found to be larger for PDR treatments than for HDR treatments, as it is influenced by the source activity, dwell times and number of radiation pulses. The overall increase in the planned dose contributed by the transit dose in a typical intracavitary PDR treatment was estimated to be <2%, but much higher for interstitial treatments. This study shows that the effect of the transit dose on common clinical intracavitary PDR brachytherapy treatments is practically negligible, but requires attention in highly fractionated large volume interstitial treatments.

Fundamental form of a population TCP model in the limit of large heterogeneity.

A population tumor control probability (TCP) model for fractionated external beam radiotherapy, based on Poisson statistics and in the limit of large parameter heterogeneity, is studied. A reduction of a general eight-parameter TCP equation, which incorporates heterogeneity in parameters characterizing linear-quadratic radiosensitivity, repopulation, and clonogen number, to an equation with four parameters is obtained. The four parameters represent the mean and standard deviation for both clonogen number and a generalized radiosensitivity that includes linear-quadratic and repopulation descriptors. Further, owing to parameter inter-relationship, it is possible to express these four parameters as three ratios of parameters in the large heterogeneity limit. These ratios can be directly linked to two defining features of the TCP dose response: D50 and gamma50. In the general case, the TCP model can be written in terms of D50, gamma50 and a third parameter indicating the ratio of the levels of heterogeneity in clonogen number and generalized radiosensitivity; however, the third parameter is unnecessary when either of these two sources of heterogeneity is dominant. It is shown that heterogeneity in clonogen number will have little impact on the TCP formula for clinical scenarios, and thus it will generally be the case that the fundamental form of the Poisson-based population TCP model can be specified completely in terms of D50 and gamma50: TCP= 1/2 erfc[square root of pi(gamma50)(D50/D-1)]. This implies that limited radiobiological information can be determined by the analysis of dose response data: information about parameter ratios can be ascertained, but knowledge of absolute values for the fundamental radiobiological parameters will require independent auxiliary measurements.